JPS61291511A - Dermatic agent - Google Patents
Dermatic agentInfo
- Publication number
- JPS61291511A JPS61291511A JP13328185A JP13328185A JPS61291511A JP S61291511 A JPS61291511 A JP S61291511A JP 13328185 A JP13328185 A JP 13328185A JP 13328185 A JP13328185 A JP 13328185A JP S61291511 A JPS61291511 A JP S61291511A
- Authority
- JP
- Japan
- Prior art keywords
- carbon dioxide
- acid
- dioxide gas
- gas
- oxygen gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は炭酸ガス及び酸素ガスを含有、発生する皮膚科
に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to dermatology containing and generating carbon dioxide gas and oxygen gas.
本明細書において皮膚科とは、直接皮膚に適用する剤を
の組成物、すなわち、皮膚及び毛髪化粧料、皮膚外用剤
並びに浴用剤を相称する。In this specification, dermatology refers to compositions that are applied directly to the skin, ie, skin and hair cosmetics, external skin preparations, and bath preparations.
従来、炭酸ガスは優れた血行促進作用を有することが知
られており、創傷の治療及び末梢動脈の慢性閉塞性疾患
の虚血肢における難治性潰瘍の治療を目的として皮膚外
用剤、皮膚、毛根の新陳代謝を活発にすることを目的と
して皮膚及び毛髪化粧料、更に疲労回復、肩こシ、腰痛
、痔疾などに対する効果を目的として浴用剤にそれぞれ
配合され、その効果を発揮している。Conventionally, carbon dioxide gas has been known to have an excellent blood circulation promoting effect, and has been used in external preparations for skin, skin, and hair roots for the purpose of treating wounds and intractable ulcers in the ischemic limbs of chronic occlusive diseases of peripheral arteries. It is used in skin and hair cosmetics to activate the metabolism of the skin, and in bath preparations to help relieve fatigue, stiff shoulders, lower back pain, hemorrhoids, etc., and has shown its effectiveness.
しかしながら、皮膚科における炭酸ガスの血行促進効果
を更に向上せしめることが要望されていたO
〔簡題点を解決するための手段〕
本発明者らは皮膚科について炭酸ガスと他の物質との組
合せについて種々検討をおこなっていたところ、酸素ガ
スとの組合せにより炭酸ガスの血行促進作用が向上し、
皮膚外用剤においては創傷治療促進効果が、皮膚及び毛
髪化粧料においては肌及び毛髪のしっとり感が、浴用剤
においては疲労回復、肩こり等に対する効果がそれぞれ
著しく高くなることを見出し、本発明を完成した。However, it has been desired to further improve the blood circulation promoting effect of carbon dioxide gas in dermatology. After conducting various studies on carbon dioxide gas, we found that the blood circulation promoting effect of carbon dioxide gas was improved when combined with oxygen gas.
The present invention was completed after discovering that external skin preparations have a significantly higher effect on promoting wound healing, skin and hair cosmetics on moisturizing the skin and hair, and bath preparations on relieving fatigue and relieving stiff shoulders. did.
したがって、本発明は炭酸ガス若しくは炭酸ガス発生物
質と酸素ガス若しくは酸素ガス発生物質を含有する皮膚
科を提供するものである。Accordingly, the present invention provides a dermatological product containing carbon dioxide or a carbon dioxide gas-generating substance and oxygen gas or an oxygen gas-generating substance.
本発明の皮膚科の態様としては、(1)炭酸ガス又は/
及び酸素ガスを常圧若しくは加圧下に皮膚科基剤に溶解
若しくは溶存せしめ、これを密封容器に充填せしめたも
の(2)炭酸ガス又は/及び酸素ガスをゼオライト、シ
クロデキストリン若しくはその誘導体等の保持物質に吸
着、保持せしめ、これを皮膚科基剤に配合したもの及び
(3)反応により炭酸ガス又は/及び酸素ガスを発生す
る物質を皮膚科基剤に配合し、用時に反応せしめるもの
並びに(1)〜(3)の組合せが挙げられる。Dermatological aspects of the present invention include (1) carbon dioxide or/
and oxygen gas dissolved or dissolved in a dermatological base under normal or pressurized conditions and filled in a sealed container (2) Carbon dioxide and/or oxygen gas retained in zeolite, cyclodextrin, or its derivatives, etc. (3) A substance that is adsorbed and retained by a substance and blended with a dermatological base; (3) A substance that generates carbon dioxide gas and/or oxygen gas upon reaction is blended with a dermatological base and reacted at the time of use; Examples include combinations of 1) to (3).
(1)の態様の皮膚科は、一般にはまず皮膚科基剤を調
製し、これを耐圧容器に充填した後炭酸ガス及び/又は
酸素ガスを吹き込むことKより調製される。The dermatological treatment according to the embodiment (1) is generally prepared by first preparing a dermatological base, filling it into a pressure-resistant container, and then blowing carbon dioxide gas and/or oxygen gas into the container.
(2)の態様の皮膚科の調製は、ゼオライト、シフロブ
キス) IJン若しくはその誘導体等の保持物質と炭酸
ガス又は/及び酸素ガスを好ましくは無水条件下で常圧
下若しくは加圧下、例えば1〜10kP/、lの圧力下
で接触、吸着せしめ、これを常法により皮膚科基剤に配
合することによシおこなわれる。保持物質として用いら
れるゼオライトとしては、天然ゼオライト、合成ゼオラ
イトのいずれであるかを問わないが、不純物等の夾雑物
の少ない次の一般式で表わされる合成ゼオライトが好ま
しい0
(M2/nO)x ” A&Os・(S tOt )y
・(Hz O)2(式中、Mは原子価nの金属原子を、
Xは0.7〜i、s、yは0.8〜I O、zは0以上
の数を示す。)
一般式の合成ゼオライトのうち、Mで示される金属原子
としてはナトリウム、カリウム、カルシウム、マグネシ
ウム等が挙げられ、2としてはOlすなわち実質的に水
分を含有しないものが好ましい。また、シクロデキスト
リンとしてばα−シクロデキストリン、β−シクロデキ
ストリン、γ−シクロデキストリンなどが使用される。The dermatological preparation according to the aspect (2) is carried out by combining a holding substance such as zeolite, schiflovkis, or a derivative thereof with carbon dioxide gas or/and oxygen gas, preferably under anhydrous conditions and under normal pressure or pressurization, e.g. 1 to 10 kP. This is carried out by contacting and adsorbing under a pressure of /, liter, and blending this into a dermatological base by a conventional method. The zeolite used as a retention substance may be either a natural zeolite or a synthetic zeolite, but a synthetic zeolite represented by the following general formula with less impurities and other impurities is preferred. A&Os・(S tOt )y
・(Hz O)2 (wherein M is a metal atom with a valence of n,
X represents 0.7 to i, s represents 0.8 to IO, and z represents a number of 0 or more. ) Among the synthetic zeolites of the general formula, metal atoms represented by M include sodium, potassium, calcium, magnesium, etc., and 2 is preferably OI, that is, one that does not substantially contain water. Further, as the cyclodextrin, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, etc. are used.
更にシクロデキストリン誘導体としては、グルコシル−
α−’/クロfキストリン、グルコシル−β−シクロデ
キストリン、グルコシル−γ−シクロデキストリン、マ
ルトシル−α−シクロデキストリン、マルトトリオシル
−α−シクロデキストリンなどの分枝シクロデキストリ
ン:0−ジ−メチル−β−シクロデキストリン、0−ト
リーメチル−β−シクロデキストリンなどのメチル化シ
クロデキストリン;シクロデキストリンをエピクロルヒ
ドリンで架橋した低重合ポリマーなとのシクロデキスト
リンポリマー;アシル化シクロデキストリン、アルチル
化シクロデキストリン、アミン化シクロデキストリンな
どが使用される。Furthermore, as a cyclodextrin derivative, glucosyl-
Branched cyclodextrin such as α-'/crof-kistrin, glucosyl-β-cyclodextrin, glucosyl-γ-cyclodextrin, maltosyl-α-cyclodextrin, maltotriosyl-α-cyclodextrin: 0-di-methyl- Methylated cyclodextrin such as β-cyclodextrin, 0-trimethyl-β-cyclodextrin; cyclodextrin polymers such as low polymerization polymers made by crosslinking cyclodextrin with epichlorohydrin; acylated cyclodextrin, altylated cyclodextrin, aminated cyclodextrin Cyclodextrin etc. are used.
炭酸ガスをゼオライトに接触、吸着せしめる場合、常温
においてゼオライ)100.9あたり、5I以上吸着さ
せることが好ましい。又、酸素を吸着させる場合には、
ゼオライト100/、iたり、0.5g以上吸着させる
ことが好ましい。When carbon dioxide is brought into contact with and adsorbed on zeolite, it is preferable to adsorb 5 I or more per 100.9 (zeolite) at room temperature. In addition, when adsorbing oxygen,
It is preferable to adsorb 0.5 g or more of zeolite per 100 g of zeolite.
また、炭酸ガスをシクロデキストリン若しくはその誘導
体に接触、吸着せしめる場合は、1kg/crI以上、
好マレ<は5〜15kg/cIIノ圧力下、30’C以
下、好ましくは20℃以下の温度条件でおこなうことが
好ましい。なお、用いるシクロデキストリン若しくはそ
の誘導体は実質的に水分を含有しないものが好ましい。In addition, when carbon dioxide gas is brought into contact with and adsorbed on cyclodextrin or its derivatives, 1 kg/crI or more,
It is preferable to carry out the reaction under a pressure of 5 to 15 kg/cII and at a temperature of 30° C. or less, preferably 20° C. or less. Note that the cyclodextrin or its derivative used preferably contains substantially no water.
斯くして得られるシフロブキス) IJン若しくはその
誘導体の炭酸ガス吸着量は用途に応じて調製可能である
が、ゼオライ)100I当シ2g以上であることが好ま
しい。The amount of carbon dioxide gas adsorbed by the thus obtained Sifurobukis IJ or its derivatives can be adjusted depending on the application, but it is preferably 2 g or more per 100 I Zeolite.
(3)の態様の皮膚科で用いる炭酸ガス発生物は、反応
によって炭酸ガスを発生するものであれば良く、就中炭
酸塩と酸の組合せが好ましい。The carbon dioxide gas generator used in dermatology according to the aspect (3) may be any substance that generates carbon dioxide gas by reaction, and a combination of carbonate and acid is particularly preferred.
炭酸塩としては、例えば炭酸水素ナトリウム、炭酸ナト
リウム、セスキ炭酸ナトリウム、炭酸水素カリウム、炭
酸カリウム、セスキ炭酸カリウム、炭酸水素アンモニウ
ム塩、炭酸アンモニウム塩、セスキ炭酸アンモニウム塩
等が挙げられ、これらは単独又は2f11以上を組合わ
せて使用できる。Examples of carbonates include sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, potassium bicarbonate, potassium carbonate, potassium sesquicarbonate, ammonium bicarbonate, ammonium carbonate, and ammonium sesquicarbonate, which may be used alone or in combination. 2f11 or more can be used in combination.
また、酸としては、有機酸及び無機酸の何れも使用でき
るが、水溶性で固体のものが好ましい。Further, as the acid, both organic acids and inorganic acids can be used, but water-soluble and solid acids are preferred.
有機酸としては、例えばギ酸、酢酸、プロピオン酸、酪
酸、吉草酸等の直鎖脂肪酸;シュウ酸、マロン酸、コハ
ク酸、グルタル酸、アジピン酸、ピメリン酸、フマル酸
、マレイン酸、フタル酸、インフタル酸、テレフタル酸
等のジカルボン酸;グルタミン酸、アスパラギン酸等の
酸性アミノ酸;クリコール酸、乳酸、ヒドロキシアクリ
ル酸、α−オキシ酪酸、グリセリン酸、タルトロン酸、
すンゴ酸、酒石酸、クエン酸、サリチル酸(o 、 m
。Examples of organic acids include straight chain fatty acids such as formic acid, acetic acid, propionic acid, butyric acid, and valeric acid; oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, fumaric acid, maleic acid, phthalic acid, Dicarboxylic acids such as inphthalic acid and terephthalic acid; acidic amino acids such as glutamic acid and aspartic acid; glycolic acid, lactic acid, hydroxyacrylic acid, α-oxybutyric acid, glyceric acid, tartronic acid,
Sungic acid, tartaric acid, citric acid, salicylic acid (o, m
.
p)、没食子酸、マンテル酸、トロバ酸、アスコルビン
酸、グルコン酸等のオキシ酸;桂皮酸、安息香酸、フェ
ニル酢酸、ニコチン酸、カイニン酸、ソルビン酸、ピロ
リドンカルボン酸、トリメリット酸、ベンゼンスルホン
酸、トルエンスルホン酸並びにこれら有機酸の酸性塩が
挙げられる。無機酸としては、例えば、リン酸、リン酸
二水素カリウム、リン酸二水素ナトリウム、亜硫酸ナト
リウム、亜硫酸カリウム、ピロ亜硫酸ナトリウム(メタ
重亜硫酸ナトリウム)、ピロ亜硫酸カリウム(メタ重亜
硫酸カリウム)、酸性へキサメタリン酸ナトリウム、酸
性へキサメタリン酸カリウム、酸性ピロリン酸ナトリウ
ム、酸性ビロリン酸カリウム、スルファミン酸等が挙げ
られる。就中、コハク酸、酒石酸、リンゴ酸、クエン酸
等のカルボン酸が好ましい。p), oxyacids such as gallic acid, mantelic acid, trobic acid, ascorbic acid, gluconic acid; cinnamic acid, benzoic acid, phenylacetic acid, nicotinic acid, kainic acid, sorbic acid, pyrrolidonecarboxylic acid, trimellitic acid, benzenesulfone acid, toluenesulfonic acid, and acid salts of these organic acids. Examples of inorganic acids include phosphoric acid, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium sulfite, potassium sulfite, sodium pyrosulfite (sodium metabisulfite), potassium pyrosulfite (potassium metabisulfite), acidic Examples include sodium xametaphosphate, acidic potassium hexametaphosphate, acidic sodium pyrophosphate, acidic potassium pyrophosphate, and sulfamic acid. Among these, carboxylic acids such as succinic acid, tartaric acid, malic acid, and citric acid are preferred.
また、酸素発生物としては、反応によって酸素を発生す
るものであればいずれも使用できるが、過ホウ酸ナトリ
ウム、過炭酸ナトリウム、過炭酸カリウム、過酸化水素
−尿素錯塩などを利用することが好ましい。In addition, as the oxygen generator, any substance that generates oxygen through reaction can be used, but it is preferable to use sodium perborate, sodium percarbonate, potassium percarbonate, hydrogen peroxide-urea complex salt, etc. .
本発明の皮膚科においては、炭酸ガスは60 ppm以
上、酸素は300 ppm以上含有、発生されることが
好ましく、例えば(2)の態様におけるゼオライト、シ
クロデキストリンの配合量は0.1〜5重量%であるこ
とが好ましい。In the dermatology of the present invention, it is preferable to generate carbon dioxide gas containing 60 ppm or more and oxygen containing 300 ppm or more. For example, in the embodiment (2), the blending amount of zeolite and cyclodextrin is 0.1 to 5% by weight. % is preferable.
本発明皮膚科の具体的剤型としては、クリーム、ハック
、美容ハウダー、ファンデーション、口紅、洗浄剤など
の皮膚化粧料:ヘアクリーム、シャンプー、リンスなど
の毛髪化粧料;バスオイル、バブルバスなどの浴用剤;
軟膏、ローション、スプレー、リニメント、パスタ、パ
ップなとの皮膚外用剤等々が挙げられる。Specific dosage forms for the dermatology of the present invention include skin cosmetics such as creams, hacks, beauty howders, foundations, lipsticks, and cleansers; hair cosmetics such as hair creams, shampoos, and conditioners; and bath oils and bubble baths. Bath preparation;
Examples include ointments, lotions, sprays, liniments, pasta, poultices, and other skin preparations.
本発明の皮膚科には更に必要に応じ、殺菌剤、消炎剤、
保湿剤、創傷治癒促進剤など各種の薬効剤の他、通常上
述の皮膚科に用いられる各種の基剤を用いることができ
、種々の剤型とすることが可能である。The dermatology of the present invention further includes disinfectants, anti-inflammatory agents,
In addition to various medicinal agents such as moisturizers and wound healing promoters, various bases commonly used in dermatology as described above can be used, and various dosage forms can be used.
本発明の皮膚科は、創傷治癒促進効果が高く、肌をしつ
とりさせる効果が非常に高いものである。The dermatological agent of the present invention has a high effect of promoting wound healing and a very high effect of moisturizing the skin.
本発明の皮膚科のこれらの効果は、炭酸ガスの血流増加
作用と酸素の適用による局所酸素濃度の上昇との相乗作
用によるものと考えられる。These dermatological effects of the present invention are thought to be due to the synergistic effect of the blood flow increasing effect of carbon dioxide gas and the increase in local oxygen concentration due to the application of oxygen.
次に本発明の皮膚科の効果を下記方法によって評価した
結果を示す。Next, the results of evaluating the dermatological effects of the present invention using the following method will be shown.
評価1:創傷治癒促進効果
体重150y前後のウィスター系雄性ラットを1群8匹
とし、背部皮膚を除毛した後、ベントパルビタールナト
リウム麻酔下に正中線で対称になるように左右に約1儂
の皮膚切開を行ない、中心部で1ケ所縫合した。縫合後
、後記実施例及び比較例で得た外用剤(軟膏)を1日3
回塗布した。Evaluation 1: Effect on promoting wound healing A group of 8 male Wistar rats weighing around 150 y were given hair on their backs, and then placed under anesthesia with bentoparbital sodium for about 1 y on each side so that they were symmetrical about the midline. A skin incision was made and one suture was placed in the center. After suturing, apply the external preparation (ointment) obtained in the Examples and Comparative Examples described below 3 times a day.
Applied twice.
3白めに抜糸し、6日目に動物を殺して背部皮膚を剥離
し、創傷部を短冊形に切り取り、両端を牽引して創傷部
が開裂するまでの力を測定し、比較した。この結果を表
1に示す。The sutures were removed on the 3rd day, and on the 6th day, the animal was sacrificed, the back skin was peeled off, the wound was cut into a rectangular shape, and both ends were pulled to measure and compare the force required to rupture the wound. The results are shown in Table 1.
表1
本発明品(実施例1)がすぐれた創傷治癒促進作用を示
すことが明らかである。Table 1 It is clear that the product of the present invention (Example 1) exhibits an excellent wound healing promoting effect.
評価2:皮膚化粧料
後記実施例2及び比較例3に示す皮膚化粧料を10名の
被験者に使用してもらいこれを官能評価した。使用は、
1週間とした0
結果を表2に示した。Evaluation 2: Skin cosmetics The skin cosmetics shown in Example 2 and Comparative Example 3 described later were used by 10 subjects and subjected to sensory evaluation. The use is
Table 2 shows the results after one week.
以下余白
表2
本発明品(実施例2)がすぐれていることが明らかであ
る。Margin Table 2 below: It is clear that the product of the present invention (Example 2) is superior.
次に実施例を示すが、本発明はこれらの実施例に限定さ
れるものではない。Examples will be shown next, but the present invention is not limited to these examples.
実施例1
軟1!F(皮膚外用剤)
精製ラノリン 5部
白色ワセリン 76部
サすシミツロウ 4部
″′1炭酸ガス含有ゼオライト 5部100部
+1炭酸ガス含有ゼオライトは、ゼオライト(ゼオラム
4−A;東洋ソーダ(株)製)を約30000で脱水し
、5 kg/論の圧力で炭酸ガスを吸着させたものを用
いた。ゼオライト100gに対し、11gの炭酸ガスが
吸着していた。Example 1 Soft 1! F (external skin preparation) Purified lanolin 5 parts White petrolatum 76 parts Sasu beeswax 4 parts'''1 Carbon dioxide-containing zeolite 5 parts 100 parts + 1 Carbon dioxide-containing zeolite is zeolite (Zeolam 4-A; manufactured by Toyo Soda Co., Ltd.) ) was dehydrated at about 30,000 ml and carbon dioxide was adsorbed at a pressure of 5 kg/liter.11 g of carbon dioxide was adsorbed to 100 g of zeolite.
骨2酸素含有ゼオライトは、ゼオライト(ゼオラム4−
A)を約300℃で脱水し、3リ一の圧力で酸素を吸着
させたものを用いた。ゼオライ)100.9に対し、1
.2gの酸素を吸着していた
実施例2
皮膚化粧料ニ
スクワラン 50.0部ヒ、マシ油
34.5部”1炭酸ガス吸着ゼオ
ライト5.0部
”2酸素吸着ゼオライ) io、o部ノーメ
ントール 0.1部100.0部
実施例3
皮膚化粧料ニ
スクワラン 84.95部メチルポリ
シロキサン 10.00部アズレン
0.05部100.00部
上記を混合後、耐圧容器に入れ、酸素を吹きこみながら
3気圧に3時間保った後、製品とする。Bone 2 oxygen-containing zeolite is zeolite (Zeolam 4-
A) was dehydrated at about 300° C. and oxygen was adsorbed at a pressure of 3 liters. Zeolite) 100.9 to 1
.. Example 2 Skin cosmetics Nisqualan 50.0 parts arsenic oil adsorbed 2g of oxygen
34.5 parts "1 Carbon dioxide adsorption zeolite 5.0 parts" 2 Oxygen adsorption zeolite) io, o part No menthol 0.1 part 100.0 parts Example 3 Skin cosmetic Nisqualane 84.95 parts Methyl polysiloxane 10 .00 part Azur Lane
0.05 parts 100.00 parts After mixing the above ingredients, the mixture is placed in a pressure-resistant container and maintained at 3 atm for 3 hours while blowing oxygen, and then used as a product.
実施例4
浴用剤:
炭酸水素ナトリウム 31部
炭酸ナトリウム 12部コハク酸
38部
芒硝 3部
”2酸素吸着ゼオライト 10部”1炭酸ガス
吸着ゼオライト 5部100部
比較例1
実施例1の炭酸ガス吸着ゼオライト、酸素吸着ゼオライ
トをゼオライトに変えた以外は実施例1と同様にして軟
膏を製した。Example 4 Bath agent: Sodium hydrogen carbonate 31 parts Sodium carbonate 12 parts Succinic acid
38 parts Glauber's salt 3 parts 2 Oxygen adsorption zeolite 10 parts 1 Carbon dioxide adsorption zeolite 5 parts 100 parts Comparative Example 1 Same as Example 1 except that the carbon dioxide adsorption zeolite and oxygen adsorption zeolite in Example 1 were changed to zeolite. An ointment was made.
比較例2
実施例1の酸素ガス吸着ゼオライトをゼオライトに変え
た以外は実施例1と同様にして軟膏を製した。Comparative Example 2 An ointment was produced in the same manner as in Example 1, except that the oxygen gas adsorbing zeolite in Example 1 was replaced with zeolite.
比較例3
実施例2の炭酸ガス吸着ゼオライト、酸素吸着ゼオライ
トをゼオライトに変えた以外は実施例2と同様にして化
粧料を裂した。Comparative Example 3 A cosmetic was prepared in the same manner as in Example 2 except that the carbon dioxide adsorbing zeolite and oxygen adsorbing zeolite in Example 2 were replaced with zeolite.
以上that's all
Claims (1)
くは酸素ガス発生物質を含有する皮膚料。1. A skin material containing carbon dioxide gas or a carbon dioxide gas generating substance and oxygen gas or an oxygen gas generating substance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13328185A JPS61291511A (en) | 1985-06-19 | 1985-06-19 | Dermatic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13328185A JPS61291511A (en) | 1985-06-19 | 1985-06-19 | Dermatic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61291511A true JPS61291511A (en) | 1986-12-22 |
JPH0535123B2 JPH0535123B2 (en) | 1993-05-25 |
Family
ID=15100971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13328185A Granted JPS61291511A (en) | 1985-06-19 | 1985-06-19 | Dermatic agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61291511A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62294604A (en) * | 1986-06-13 | 1987-12-22 | Mitsui Toatsu Chem Inc | Novel hair detergent composition |
JPH0236115A (en) * | 1988-07-23 | 1990-02-06 | San Paruko Kk | Bathing agent |
JPH07309744A (en) * | 1994-05-18 | 1995-11-28 | Miton House:Kk | Solid bathing agent generating oxygen |
WO1999029292A1 (en) * | 1997-12-09 | 1999-06-17 | Hans Joachim Schwanitz | Use of carboxylic acid to stabilize or improve epidermal synthesized ceramide |
GB2343626A (en) * | 1998-11-13 | 2000-05-17 | Russell H Swenson | Carbon dioxide expressing compositions |
JP2008050316A (en) * | 2006-08-25 | 2008-03-06 | Kao Corp | Skin preparation for external use |
JP2008515948A (en) * | 2004-10-12 | 2008-05-15 | メッドドロップ テクノロジー アーゲー | Drugs and systems for transdermal formulations |
WO2009142275A1 (en) * | 2008-05-22 | 2009-11-26 | 株式会社ソリュース | Mousse-type oil-and-fat composition and process for production thereof |
JP2015017346A (en) * | 2013-07-12 | 2015-01-29 | 花王株式会社 | Nanofiber sheet and method for producing the same |
JP2015044781A (en) * | 2013-08-29 | 2015-03-12 | 花王株式会社 | Skin external preparation |
-
1985
- 1985-06-19 JP JP13328185A patent/JPS61291511A/en active Granted
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62294604A (en) * | 1986-06-13 | 1987-12-22 | Mitsui Toatsu Chem Inc | Novel hair detergent composition |
JPH0236115A (en) * | 1988-07-23 | 1990-02-06 | San Paruko Kk | Bathing agent |
JPH0579047B2 (en) * | 1988-07-23 | 1993-11-01 | San Paruko Kk | |
JPH07309744A (en) * | 1994-05-18 | 1995-11-28 | Miton House:Kk | Solid bathing agent generating oxygen |
WO1999029292A1 (en) * | 1997-12-09 | 1999-06-17 | Hans Joachim Schwanitz | Use of carboxylic acid to stabilize or improve epidermal synthesized ceramide |
GB2343626A (en) * | 1998-11-13 | 2000-05-17 | Russell H Swenson | Carbon dioxide expressing compositions |
JP2008515948A (en) * | 2004-10-12 | 2008-05-15 | メッドドロップ テクノロジー アーゲー | Drugs and systems for transdermal formulations |
JP2008050316A (en) * | 2006-08-25 | 2008-03-06 | Kao Corp | Skin preparation for external use |
WO2009142275A1 (en) * | 2008-05-22 | 2009-11-26 | 株式会社ソリュース | Mousse-type oil-and-fat composition and process for production thereof |
JP5632741B2 (en) * | 2008-05-22 | 2014-11-26 | 株式会社ソリュース | Moose oil and fat composition and method for producing the same |
JP2015017346A (en) * | 2013-07-12 | 2015-01-29 | 花王株式会社 | Nanofiber sheet and method for producing the same |
JP2015044781A (en) * | 2013-08-29 | 2015-03-12 | 花王株式会社 | Skin external preparation |
Also Published As
Publication number | Publication date |
---|---|
JPH0535123B2 (en) | 1993-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2434097T3 (en) | Calcium and phosphopeptide complexes | |
JP2651366B2 (en) | Cosmetic and / or dermatological composition having a hydrophilic carrier and vitamin C mixed immediately before use | |
JP2008508215A (en) | N-acylated derivatives of dicarboxylic acids in amino acid and plant protein hydrolysates and their use in cosmetics and medicine | |
JP6082381B2 (en) | Kit for preparation of carbon dioxide-containing composition | |
CN1259861A (en) | Desensitizing dentifrice having limited astringency | |
KR20150097493A (en) | Two component compositions containing tetrabasic zinc-amino acid halide complexes and cysteine | |
JPH01110614A (en) | Aqueous hydrogen peroxide dental gel | |
WO2017127452A1 (en) | Hypochlorite formulations for wound healing | |
KR20150097494A (en) | Oral care products comprising a tetrabasic zinc - amino acid - halide complex | |
WO2018198296A1 (en) | Hydroxyapatite, cosmetic, food, and method for producing same | |
JPS61291511A (en) | Dermatic agent | |
US20080274206A1 (en) | Stabilised Oxygen Releasing Composition | |
JP2004339142A (en) | Skin cosmetic | |
US3107252A (en) | Allantoin salt | |
JP2622574B2 (en) | Bath additive | |
JP4252444B2 (en) | Use of glycoproteins for wound healing and re-epithelialization | |
JPH06227956A (en) | Cosmetic or medicinal composition | |
JP2007254443A (en) | Germanium-containing carbon dioxide formulation for external use | |
WO2011157609A2 (en) | Use of amino acid derivatives as agents for treating human perspiration, novel compounds, and compositions containing them | |
JPS61291512A (en) | Dermatic agent | |
KR102214403B1 (en) | Microneedle bonded complexed peptides and cosmetic composion comprising the same | |
CN110049756B (en) | Oral composition | |
WO2013157034A1 (en) | Composition for preparing external skin preparation | |
JPH0534324B2 (en) | ||
JP2004339143A (en) | Skin cosmetic |